Join our webinar to discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct model for your studies. Learn how current models are being used to progress combination regimens, including dual immunotherapies, and I/O agents plus other treatment modalities.
This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.
Join our webinar to discover the development and utility of CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications. Learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.
At ASCO 2017 we are bringing together recognized scientific leaders in the field of Oncology Precision Medicine to discuss the latest combination therapy approaches, translational oncology, and immuno-oncology findings. We hope that you'll join us there at Booth #17017
Join us at ADA 2017 Booth #131 to discuss our unique end to end continuum of translational in vivo platforms to overcome current challenges in modeling human diabetes in animal models. We're also presenting scientific posters of our recent research advances.
Crown Bioscience invites you to attend a symposium featuring the latest Translational Oncology Drug Discovery advances and models, with a key focus on immuno-oncology. Join the discussion on how translational oncology and immuno-oncology platforms can be applied to expedite novel cancer agents efficiently from basic research to clinical use.
Fast track your efficacy studies, cell viability assays, or antibody and inhibitor screening with any of our 60 recombinant cell lines developed specifically for preclinical cancer research.
Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.
Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.
May 23, 2017
With the creation and increased use of “new” xenograft models (such as patient-derived...
May 18, 2017
A significant challenge in the development of new anti-diabetic therapies is the lack of...
May 12, 2017
Anyone who works in preclinical and translational oncology drug development will have seen or...
May 23 - 25, 2017
Tel Aviv, Israel
May 24 - 25, 2017
June 2 - 6, 2017
June 9 - 13, 2017
San Diego, CA - Booth #131
June 21, 2017
Terrass Hotel - Paris, France
June 23, 2017
Sheraton Valley Forge Hotel, PA
June 28 - July 2, 2017
Taipei Taiwan (Booth #N202)
June 29, 2017
Hebrew University, Jerusalem
July 18, 2017
July 18 - 20, 2017
The Colonnade Hotel, Boston, MA
September 2017 TBD
San Diego, CA
September 6 - 9, 2017
September 29 - 30, 2017